What is the global market size of Interventional Oncology Market?

Interventional Oncology Market size was valued at USD 1984 million in 2021 and is poised to grow from USD 2134.78 million in 2022 to USD 4127.28 million by 2030, growing at a CAGR of 7.6% in the forecast period (2023-2030).

Who are the key vendors in the Global Interventional Oncology Market?

The market's key players are undertaking various strategic initiatives such as the signing of a collaborations, new partnership agreement, mergers and acquisitions, geographic coverage, with the goal of strengthening their product portfolio and manufacturing capacities, thereby providing a competitive advantage. In 2021, Boston Scientific (US) led the worldwide interventional oncology market. To improve its market presence and product offerings, the corporation primarily relies on growth tactics such as acquisitions and expansions. The acquisition of BTG by the firm will help it increase its product portfolio in chemoembolization, radioembolization, and ablation treatments. Boston Scientific works hard to get regulatory and reimbursement approvals. As part of its long-term growth plan, the firm invests in both fast-growing and new areas in order to improve its position in the global healthcare sector. 'Medtronic (Ireland)', 'Teleflex (US)', 'Boston Scientific Corporation', 'BTG International Ltd. (acquired by Boston Scientific)', 'Cook Medical Inc.', 'AngioDynamics Inc.', 'Terumo Corporation', 'Merit Medical Systems Inc.', 'Johnson & Johnson Services Inc.', 'MedWaves, Inc.', 'Healthtronics Inc.', 'Trod Medical', 'InSightec Ltd.', 'Sirtex Medical Limited', 'Sanarus Technologies, LLC', 'C.R. Bard, Inc. (acquired by Becton, Dickinson and Company)', 'Guerbet Group', 'Varian Medical Systems, Inc.', 'Nanobiotix SA', 'OncoTherapy Science, Inc.'

What is the key driver of Global Interventional Oncology Market?

Patients' Preference for Least Invasive Therapies Is Growing

What is the key market trend for Global Interventional Oncology Market?

The organisations are now concentrating on improving performance by incorporating robotics technology into interventional oncology equipment. Robotic systems have improved accuracy and efficiency by combining image-based planning and navigation with the placement of various instruments for the targeted body part. Furthermore, the fast increase in cancer incidence worldwide, along with a growing desire for less invasive therapies, is boosting market growth throughout the projection period. In addition, increased government and private financing for cancer research, particularly for treatment devices that encourage early detection and enhance survival rates, has fuelled market expansion. Interventional Oncology therapies can be quite beneficial to patients.

Which region accounted for the largest share in Interventional Oncology Market?

In 2021, North America held the largest share of the global interventional oncology market, followed by Europe, Asia-Pacific, Latin America, and the Middle East and Africa. However, Asia-Pacific will be the fastest expanding regional market due to the region's faster economic expansion and increased government attention on the healthcare sector. Furthermore, government initiatives to develop healthcare facilities, rising cancer incidence and prevalence, rising awareness of overall health and treatment availability, increasing middle-class population and disposable income, increasing health insurance penetration, and a growing ageing population in the region are key factors driving the growth of the Asia-Pacific interventional oncology market.

Interventional Oncology Market Size, Share, Growth Analysis, By Product (Embolization Devices, Ablation Devices), By Cancer Type (Liver Cancer, Kidney Cancer), By Procedure (TARE/SIRT, TACE), By End-User (Hospitals, Ambulatory Surgery Centers), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35G2238 | Region: Global | Published Date: September, 2024
Pages: 242 | Tables: 147 | Figures: 78

Interventional Oncology Market Competitive Landscape

Interventional Oncology Market Top Player's Company Profiles

Boston Scientific Corporation (US)
Medtronic plc (Ireland)
Johnson & Johnson (US)
Terumo Corporation (Japan)
Merit Medical Systems, Inc. (US)
Teleflex, Inc. (US)
AngioDynamics, Inc. (US)
Becton, Dickinson and Company (US)
Healthtronics, Inc. (US)
Trod Medical (US)
Sanarus Technologies, Inc. (US)
Imbiotechnologies Ltd. (UK)
Medwaves, Inc. (US)
IceCure Medical (Israel)
Cook Medical (US)
Profound Medical Corp. (Canada)
Sirtex Medical (Australia)
Baylis Medical Company, Inc. (Canada)
Accuray (US)
Alpinion Medical Systems (South Korea)

Interventional Oncology Market Recent Development

In September 2023, Cook Medical announced the launch of its latest embolization device, designed for treating tumors more effectively with improved precision. This innovative device utilizes advanced imaging technology, enabling interventional radiologists to achieve better targeting and reduced complication rates, enhancing patient outcomes in interventional oncology procedures.
In August 2023, Boston Scientific unveiled its next-generation radiofrequency ablation system for liver tumors. This system integrates advanced imaging techniques and real-time monitoring capabilities, allowing for more accurate treatment delivery. The launch reflects Boston Scientific's commitment to advancing minimally invasive oncology therapies and improving patient experiences during interventional procedures.
In July 2023, Medtronic announced a significant collaboration with a leading oncology center to evaluate the effectiveness of its novel drug-coated balloons for treating liver cancers. This partnership aims to enhance clinical outcomes by leveraging Medtronic's innovative technologies, focusing on providing safer and more effective interventional oncology treatments for patients globally.

Interventional Oncology Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Interventional Oncology Market size was valued at USD 2.17 billion in 2022 and is poised to grow from USD 2.31 billion in 2023 to USD 3.92 billion by 2031, growing at a CAGR of 6.8% in the forecast period (2024-2031).

The competitive landscape of the global interventional oncology market is characterized by a mix of established players and emerging companies focusing on innovation and technological advancements. Key players include Medtronic, Boston Scientific, Siemens Healthineers, and Terumo Corporation, all of which are actively developing advanced devices and therapies. These companies emphasize collaborations and strategic partnerships to enhance their product portfolios and improve patient outcomes, driving competition and fostering continuous improvement in interventional oncology solutions worldwide. 'Boston Scientific Corporation (US)', 'Medtronic plc (Ireland)', 'Johnson & Johnson (US)', 'Terumo Corporation (Japan)', 'Merit Medical Systems, Inc. (US)', 'Teleflex, Inc. (US)', 'AngioDynamics, Inc. (US)', 'Becton, Dickinson and Company (US)', 'Healthtronics, Inc. (US)', 'Trod Medical (US)', 'Sanarus Technologies, Inc. (US)', 'Imbiotechnologies Ltd. (UK)', 'Medwaves, Inc. (US)', 'IceCure Medical (Israel)', 'Cook Medical (US)', 'Profound Medical Corp. (Canada)', 'Sirtex Medical (Australia)', 'Baylis Medical Company, Inc. (Canada)', 'Accuray (US)', 'Alpinion Medical Systems (South Korea)'

The increasing prevalence of cancer globally is a significant driver of the interventional oncology market. With a growing aging population and lifestyle-related risk factors, the demand for effective cancer treatment options is escalating. This trend prompts healthcare providers to adopt innovative interventional procedures, enhancing patient outcomes and survival rates.

There is a significant trend toward minimally invasive interventional oncology techniques, driven by their ability to reduce recovery times and complications. Patients and healthcare providers increasingly favor these approaches, leading to the development and integration of advanced technologies that enhance precision and effectiveness in cancer treatment.

North America dominates the global interventional oncology market share due to a combination of advanced healthcare infrastructure, high levels of investment in research and development, and a strong presence of key market players. The region benefits from a growing number of cancer cases, which drives demand for innovative treatment options. Additionally, robust reimbursement policies and the adoption of minimally invasive techniques have contributed to increased procedure volumes. The presence of leading hospitals and specialized oncology centers facilitates cutting-edge treatments, further enhancing patient access. Furthermore, ongoing collaborations between healthcare providers and technology developers are accelerating advancements, solidifying North America's leadership in interventional oncology.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Interventional Oncology Market Size, Share, Growth Analysis, By Product (Embolization Devices, Ablation Devices), By Cancer Type (Liver Cancer, Kidney Cancer), By Procedure (TARE/SIRT, TACE), By End-User (Hospitals, Ambulatory Surgery Centers), By Region - Industry Forecast 2025-2032

Interventional Oncology Market Competitive Landscape

Interventional Oncology Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Interventional Oncology Market?

Who are the key vendors in the Interventional Oncology Market?

What is the key driver of Interventional Oncology Market?

What is the key market trend for Interventional Oncology Market?

Which region accounted for the largest share in Interventional Oncology Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300